(ICLR) ICON - Overview
Stock: Clinical Trials, Data Analysis, Laboratory Services, Consulting
| Risk 5d forecast | |
|---|---|
| Volatility | 52.7% |
| Relative Tail Risk | -17.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.45 |
| Alpha | -65.83 |
| Character TTM | |
|---|---|
| Beta | 1.080 |
| Beta Downside | 0.391 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.87% |
| CAGR/Max DD | -0.27 |
EPS (Earnings per Share)
Revenue
Risks
Description: ICLR ICON March 04, 2026
ICON Public Limited Company (ICLR) is a contract research organization (CRO) offering outsourced development and commercialization services globally. The company supports pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations.
ICLRs services span the entire clinical development process, from early compound selection through Phase I-IV clinical trials. This includes clinical trial management, data solutions, and consulting. CROs like ICLR are critical to the drug development pipeline, enabling pharmaceutical companies to bring new therapies to market more efficiently.
The company also provides a range of laboratory services, such as bioanalytical and central laboratory testing, and offers full-service or functional service partnerships. This diversified service offering is typical for large CROs, allowing them to capture various revenue streams within the clinical research sector.
Additional offerings include adaptive trials, decentralized clinical trials, medical imaging, and real-world intelligence. These services reflect evolving trends in clinical research, such as the increasing adoption of technology to improve trial efficiency and patient access. Further research on ValueRay can provide detailed financials and competitive analysis.
Headlines to watch out for
- Biopharma R&D spending directly impacts ICONs service demand
- Clinical trial outsourcing trends drive revenue growth
- Regulatory changes in drug development affect service offerings
- Competition from other CROs pressures pricing and market share
- Labor costs for scientific staff influence profit margins
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 599.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.11 > 1.0 |
| NWC/Revenue: 2.34% < 20% (prev 11.56%; Δ -9.22% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.18b > Net Income 599.5m |
| Net Debt (3.10b) to EBITDA (1.18b): 2.63 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (78.1m) vs 12m ago -6.43% < -2% |
| Gross Margin: 26.85% > 18% (prev 0.30%; Δ 2.66k% > 0.5%) |
| Asset Turnover: 48.06% > 50% (prev 48.26%; Δ -0.20% > 0%) |
| Interest Coverage Ratio: 3.96 > 6 (EBITDA TTM 1.18b / Interest Expense TTM 199.4m) |
Altman Z'' 1.17
| A: 0.01 (Total Current Assets 3.41b - Total Current Liabilities 3.22b) / Total Assets 16.51b |
| B: 0.14 (Retained Earnings 2.31b / Total Assets 16.51b) |
| C: 0.05 (EBIT TTM 790.0m / Avg Total Assets 16.86b) |
| D: 0.31 (Book Value of Equity 2.23b / Total Liabilities 7.17b) |
| Altman-Z'' Score: 1.17 = BB |
Beneish M -3.00
| DSRI: 0.98 (Receivables 2.80b/2.94b, Revenue 8.10b/8.31b) |
| GMI: 1.10 (GM 26.85% / 29.58%) |
| AQI: 1.02 (AQ_t 0.76 / AQ_t-1 0.75) |
| SGI: 0.98 (Revenue 8.10b / 8.31b) |
| TATA: -0.04 (NI 599.5m - CFO 1.18b) / TA 16.51b) |
| Beneish M-Score: -3.00 (Cap -4..+1) = A |
What is the price of ICLR shares?
Over the past week, the price has changed by -8.27%, over one month by +5.73%, over three months by -46.67% and over the past year by -45.05%.
Is ICLR a buy, sell or hold?
- StrongBuy: 11
- Buy: 0
- Hold: 6
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ICLR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 142.9 | 35.6% |
| Analysts Target Price | 142.9 | 35.6% |
ICLR Fundamental Data Overview March 14, 2026
P/E Forward = 8.643
P/S = 1.029
P/B = 0.9043
P/EG = 4.8025
Revenue TTM = 8.10b USD
EBIT TTM = 790.0m USD
EBITDA TTM = 1.18b USD
Long Term Debt = 2.88b USD (from longTermDebt, last quarter)
Short Term Debt = 567.9m USD (from shortTermDebt, last quarter)
Debt = 3.57b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.10b USD (from netDebt column, last quarter)
Enterprise Value = 11.44b USD (8.34b + Debt 3.57b - CCE 468.9m)
Interest Coverage Ratio = 3.96 (Ebit TTM 790.0m / Interest Expense TTM 199.4m)
EV/FCF = 11.49x (Enterprise Value 11.44b / FCF TTM 995.8m)
FCF Yield = 8.70% (FCF TTM 995.8m / Enterprise Value 11.44b)
FCF Margin = 12.29% (FCF TTM 995.8m / Revenue TTM 8.10b)
Net Margin = 7.40% (Net Income TTM 599.5m / Revenue TTM 8.10b)
Gross Margin = 26.85% ((Revenue TTM 8.10b - Cost of Revenue TTM 5.93b) / Revenue TTM)
Gross Margin QoQ = 22.32% (prev 27.84%)
Tobins Q-Ratio = 0.69 (Enterprise Value 11.44b / Total Assets 16.51b)
Interest Expense / Debt = 1.41% (Interest Expense 50.2m / Debt 3.57b)
Taxrate = 8.94% (77.7m / 869.2m)
NOPAT = 719.3m (EBIT 790.0m * (1 - 8.94%))
Current Ratio = 1.06 (Total Current Assets 3.41b / Total Current Liabilities 3.22b)
Debt / Equity = 0.38 (Debt 3.57b / totalStockholderEquity, last quarter 9.33b)
Debt / EBITDA = 2.63 (Net Debt 3.10b / EBITDA 1.18b)
Debt / FCF = 3.12 (Net Debt 3.10b / FCF TTM 995.8m)
Total Stockholder Equity = 9.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 599.5m / Total Assets 16.51b)
RoE = 6.32% (Net Income TTM 599.5m / Total Stockholder Equity 9.48b)
RoCE = 6.39% (EBIT 790.0m / Capital Employed (Equity 9.48b + L.T.Debt 2.88b))
RoIC = 5.58% (NOPAT 719.3m / Invested Capital 12.90b)
WACC = 7.31% (E(8.34b)/V(11.91b) * Re(9.89%) + D(3.57b)/V(11.91b) * Rd(1.41%) * (1-Tc(0.09)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.07%
[DCF] Terminal Value 79.20% ; FCFF base≈1.09b ; Y1≈979.9m ; Y5≈840.0m
[DCF] Fair Price = 187.2 (EV 17.40b - Net Debt 3.10b = Equity 14.30b / Shares 76.4m; r=7.31% [WACC]; 5y FCF grow -12.41% → 2.90% )
EPS Correlation: -31.43 | EPS CAGR: -45.23% | SUE: -4.0 | # QB: 0
Revenue Correlation: 72.89 | Revenue CAGR: 2.17% | SUE: 1.53 | # QB: 2
EPS next Year (2026-12-31): EPS=12.67 | Chg7d=+0.004 | Chg30d=-0.567 | Revisions Net=-7 | Growth EPS=-2.5% | Growth Revenue=-0.5%